{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T10:19:41Z","timestamp":1776248381885,"version":"3.50.1"},"reference-count":18,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Iron overload and its associated complications are major concerns in patients with transfusion-dependent \u03b2-thalassaemia (TDT). Iron chelation is an important part of TDT therapy with monotherapy or dual iron chelation being the most commonly used strategies. Evidence regarding the efficacy and safety of triple iron chelation therapy remains limited.\u00a0Case presentation: We present the case of a 21-year-old immigrant from the Middle East with TDT and a history of irregular transfusion management without chelation therapy, leading to clinically significant iron overload. She was successfully treated with the combination of deferoxamine, deferasirox and deferiprone over a course of 8 years. Triple chelation therapy led to sustained reductions in serum ferritin levels and improvement in hepatic and cardiac iron burden on follow-up MRI, with good tolerability. Conclusions: This case highlights the potential role of triple iron chelation therapy as a therapeutic strategy in TDT patients with severe iron overload. Further studies are needed to establish optimal dosing, eligible patients and long-term safety.<\/jats:p>","DOI":"10.3390\/jcm15082993","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T09:15:59Z","timestamp":1776244559000},"page":"2993","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Triple Iron Chelation in Transfusion Dependent Thalassemia: A Case Report"],"prefix":"10.3390","volume":"15","author":[{"given":"Linet","family":"Njue","sequence":"first","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"H\u00e4fliger","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7757-4753","authenticated-orcid":false,"given":"Alicia","family":"Rov\u00f3","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1056\/NEJMra2021838","article-title":"beta-Thalassemias","volume":"384","author":"Taher","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_2","unstructured":"Taher, A.T., Farmakis, D., Porter, J.B., Cappellini, M.D., and Musallam, K.M. (2025). Guidelines for the Management of Transfusion-Dependent Beta-Thalassaemia (TDT), Thalassaemia International Federation. [5th ed.]."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e221856","DOI":"10.1148\/radiol.221856","article-title":"Quantification of Liver Iron Overload with MRI: Review and Guidelines from the ESGAR and SAR","volume":"307","author":"Reeder","year":"2023","journal-title":"Radiology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"100357","DOI":"10.1016\/j.ejro.2021.100357","article-title":"Quantitative T2* imaging of iron overload in a non-dedicated center-Normal variation, repeatability and reader variation","volume":"8","author":"Liden","year":"2021","journal-title":"Eur. J. Radiol. Open"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/asheducation-2014.1.210","article-title":"Guidelines for quantifying iron overload","volume":"2014","author":"Wood","year":"2014","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/bjh.17839","article-title":"Guidelines for the monitoring and management of iron overload in patients with haemoglobinopathies and rare anaemias","volume":"196","author":"Shah","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/nyas.15052","article-title":"Combination chelation therapy","volume":"1529","author":"Aydinok","year":"2023","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"100495","DOI":"10.1016\/j.lansea.2024.100495","article-title":"Deferoxamine, deferasirox, and deferiprone triple iron chelator combination therapy for transfusion-dependent beta-thalassaemia with very high iron overload: A randomised clinical trial","volume":"30","author":"Premawardhena","year":"2024","journal-title":"Lancet Reg. Health Southeast Asia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2141.2009.07609.x","article-title":"Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: A randomized clinical trial","volume":"145","author":"Maggio","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/ejh.12507","article-title":"Efficacy and safety of a novel combination of two oral chelators deferasirox\/deferiprone over deferoxamine\/deferiprone in severely iron overloaded young beta thalassemia major patients","volume":"95","author":"Elalfy","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1182\/blood-2014-07-586677","article-title":"Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload","volume":"125","author":"Aydinok","year":"2015","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"E281","DOI":"10.1002\/ajh.26592","article-title":"An open-label, multicenter, efficacy, and safety study of deferasirox in iron-overloaded patients with non-transfusion-dependent thalassemia (THETIS): 5-year results","volume":"97","author":"Lai","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_13","first-page":"1241","article-title":"A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia","volume":"91","author":"Galanello","year":"2006","journal-title":"Haematologica"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1080\/17474086.2019.1662721","article-title":"Effect of different iron chelation regimens on bone mass in transfusion-dependent thalassemia patients","volume":"12","author":"Bordbar","year":"2019","journal-title":"Expert Rev. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e2018066","DOI":"10.4084\/mjhid.2018.066","article-title":"Deferasirox: Over a Decade of Experience in Thalassemia","volume":"10","author":"Moukalled","year":"2018","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/17474086.2017.1318052","article-title":"Deferiprone for the treatment of transfusional iron overload in thalassemia","volume":"10","author":"Belmont","year":"2017","journal-title":"Expert Rev. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e14337","DOI":"10.1111\/ijcp.14337","article-title":"A double-blind, controlled, crossover trial of amlodipine on iron overload status in transfusion dependent beta-thalassemia patients","volume":"75","author":"Karami","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e29564","DOI":"10.1002\/pbc.29564","article-title":"Comparison of the effects of calcium channel blockers plus iron chelation therapy versus chelation therapy only on iron overload in children and young adults with transfusion-dependent thalassemia: A randomized double-blind placebo-controlled trial","volume":"69","author":"Gupta","year":"2022","journal-title":"Pediatr. Blood Cancer"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/8\/2993\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T09:30:27Z","timestamp":1776245427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/8\/2993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":18,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["jcm15082993"],"URL":"https:\/\/doi.org\/10.3390\/jcm15082993","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]}}}